Is Trametinib a targeted drug?

Trametinib (Trametinib) is a targeted therapy drug. It belongs to a class of drugs called kinase inhibitors, which block the growth and spread of cancer cells through kinase activity in specific signaling pathways. Specifically, trametinib is a MEK inhibitor that acts on the MAPK/ERK signaling pathway. This pathway plays an important role in many cancers, including BRAF V600 mutation-positive malignant melanoma and non-small cell lung cancer.

By inhibitingMEK kinase activity, Trametinib can interfere with the normal function of this signaling pathway and reduce the proliferation and survival of cancer cells. Due to the targeting effect of trametinib, it can affect cancer cells more precisely and its effect is more specific than traditional chemotherapy drugs. This targeted treatment approach, which targets specific signaling pathways in cancer cells, is designed to minimize damage to healthy cells and improve treatment effectiveness.

The original drug of trametinib has been launched in China and has entered the scope of Class B medical insurance, but it may only be purchased by patients who meet the indications of trametinib, such as BRAF V600 mutation-positive unresectable or metastatic melanoma. Its price is around 10,000 to 20,000 yuan. The reimbursement ratio is different in different regions, and the price is also different, making it expensive. The price of the Turkish version of the original drug Trametinib listed overseas is around RMB 7,900 (the price may fluctuate due to the exchange rate). Generic trametinib is also produced in other countries. The price of the Lao pharmaceutical factory is around RMB 2,950 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of foreign generic drugs are basically the same as those of domestic and foreign original drugs.